<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Generic Drugs &#187; News</title>
	<atom:link href="http://www.egenericdrugs.org/category/news/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.egenericdrugs.org</link>
	<description>Generic medications info, updates and news Drugs</description>
	<lastBuildDate>Sat, 26 Mar 2011 11:20:29 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Forest Laboratories to acquire Clinical Data</title>
		<link>http://www.egenericdrugs.org/news/forest-laboratories-to-acquire-clinical-data/</link>
		<comments>http://www.egenericdrugs.org/news/forest-laboratories-to-acquire-clinical-data/#comments</comments>
		<pubDate>Fri, 25 Feb 2011 13:56:19 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2097</guid>
		<description><![CDATA[Forest Laboratories agreed to acquire Clinical Data, a specialty pharmaceutical company, for $1.2 billion. The transaction reflects a price of $30 per share in cash plus contingent consideration of up to $6 per share that may be paid upon achievement of certain commercial milestones related to its depression treatment Viibryd (vilazodone hydrochloride). Forest will finance [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/news/merck-wins-first-fosamax-state-court-case/' rel='bookmark' title='Merck wins first FOSAMAX state court case'>Merck wins first FOSAMAX state court case</a></li>
<li><a href='http://www.egenericdrugs.org/news/protect-sells-pain-drugs-patent-portfolio-to-grunenthal/' rel='bookmark' title='Protect sells pain drugs patent portfolio to Grunenthal'>Protect sells pain drugs patent portfolio to Grunenthal</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/forest-laboratories-to-acquire-clinical-data/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Learning from Recent FDA Warning Letters</title>
		<link>http://www.egenericdrugs.org/news/learning-from-recent-fda-warning-letters/</link>
		<comments>http://www.egenericdrugs.org/news/learning-from-recent-fda-warning-letters/#comments</comments>
		<pubDate>Tue, 22 Feb 2011 17:51:30 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[FDA Warning Letters]]></category>
		<category><![CDATA[Part 11 regulation]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2094</guid>
		<description><![CDATA[Learning from Recent FDA Warning Letters Related to Computer Validation and Part 11: With Clear Recommendations for Corrective and Preventive Actions. The new Part 11 regulation takes quite some time, but inspectors go out and focus inspections on computer systems and electronic-records for compliance with GMPs. What will you learn: - FDA inspections: Preparation, conducts, [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/news/congress-passed-fda-food-safety-modernization-act/' rel='bookmark' title='Congress passed FDA Food Safety Modernization Act'>Congress passed FDA Food Safety Modernization Act</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/learning-from-recent-fda-warning-letters/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanofi-Aventis to buy Genzyme</title>
		<link>http://www.egenericdrugs.org/news/sanofi-aventis-to-buy-genzyme/</link>
		<comments>http://www.egenericdrugs.org/news/sanofi-aventis-to-buy-genzyme/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 18:25:11 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[alemtuzumab]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2090</guid>
		<description><![CDATA[Sanofi-Aventis has entered into a definitve agreement to buy Genzyme for $20.1bn in cash, in addition to future payments based on the performance of Genzyme&#8217;s experimental multiple sclerosis drug (alemtuzumab MS). LGC adds PRIMACYT in-vitro products, services for drug discovery research LGC Standards, an England-based scientific company which provides analytical, forensic and diagnostic services and [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/news/protect-sells-pain-drugs-patent-portfolio-to-grunenthal/' rel='bookmark' title='Protect sells pain drugs patent portfolio to Grunenthal'>Protect sells pain drugs patent portfolio to Grunenthal</a></li>
<li><a href='http://www.egenericdrugs.org/news/boehringer-ingelheim-to-acquire-amgen-fremont-california-facility/' rel='bookmark' title='Boehringer Ingelheim to acquire Amgen Fremont California facility'>Boehringer Ingelheim to acquire Amgen Fremont California facility</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/sanofi-aventis-to-buy-genzyme/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Merck wins first FOSAMAX state court case</title>
		<link>http://www.egenericdrugs.org/news/merck-wins-first-fosamax-state-court-case/</link>
		<comments>http://www.egenericdrugs.org/news/merck-wins-first-fosamax-state-court-case/#comments</comments>
		<pubDate>Tue, 15 Feb 2011 13:32:57 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[FOSAMAX]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2087</guid>
		<description><![CDATA[Merck &#38; Co said a state court jury in New Jersey has given ruling in its favor in the Rosenberg case, discarding the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use. New England Biolabs expands PCR reagents product line New England Biolabs, a privately held company that [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/news/protect-sells-pain-drugs-patent-portfolio-to-grunenthal/' rel='bookmark' title='Protect sells pain drugs patent portfolio to Grunenthal'>Protect sells pain drugs patent portfolio to Grunenthal</a></li>
<li><a href='http://www.egenericdrugs.org/news/forest-laboratories-to-acquire-clinical-data/' rel='bookmark' title='Forest Laboratories to acquire Clinical Data'>Forest Laboratories to acquire Clinical Data</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/merck-wins-first-fosamax-state-court-case/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What&#8217;s New in Pharma</title>
		<link>http://www.egenericdrugs.org/news/whats-new-in-pharma/</link>
		<comments>http://www.egenericdrugs.org/news/whats-new-in-pharma/#comments</comments>
		<pubDate>Mon, 14 Feb 2011 13:49:52 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2080</guid>
		<description><![CDATA[Capsugel Acquires GSK’s Drug Delivery Technology Capsugel, an innovator in drug delivery systems, announced its acquisition of a novel dosage form developed by GSK Read more AndersonBrecon Opens North American Facility AndersonBrecon Clinical Services has established a new clinical services facility with packaging operations for each stage of the drug development process in both the [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/generic-drugs/natco-pharma-files-tamiflu-generic-version-anda-for-fda-approval/' rel='bookmark' title='Natco Pharma files Tamiflu generic version ANDA for FDA approval'>Natco Pharma files Tamiflu generic version ANDA for FDA approval</a></li>
<li><a href='http://www.egenericdrugs.org/news/boehringer-eli-lilly-to-develop-diabetes-compounds/' rel='bookmark' title='Boehringer, Eli Lilly to develop diabetes compounds'>Boehringer, Eli Lilly to develop diabetes compounds</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/whats-new-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA grants to Inhibitex HCV drug</title>
		<link>http://www.egenericdrugs.org/news/fda-grants-to-inhibitex-hcv-drug/</link>
		<comments>http://www.egenericdrugs.org/news/fda-grants-to-inhibitex-hcv-drug/#comments</comments>
		<pubDate>Mon, 14 Feb 2011 13:33:56 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[vFood and Drug Administration]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2077</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) has designated Inhibitex&#8217;s investigation of INX-08189, a potent guanosine nucleotide polymerase inhibitor for the treatment of chronic hepatitis C viral (HCV) infection, as a fast track development program. Lucentis Phase III study meets primary endpoint: Genentech Genentech, a member of the Roche, said RISE (FVF4170g) study evaluating monthly [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/news/protect-sells-pain-drugs-patent-portfolio-to-grunenthal/' rel='bookmark' title='Protect sells pain drugs patent portfolio to Grunenthal'>Protect sells pain drugs patent portfolio to Grunenthal</a></li>
<li><a href='http://www.egenericdrugs.org/news/boehringer-ingelheim-to-acquire-amgen-fremont-california-facility/' rel='bookmark' title='Boehringer Ingelheim to acquire Amgen Fremont California facility'>Boehringer Ingelheim to acquire Amgen Fremont California facility</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/fda-grants-to-inhibitex-hcv-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Protect sells pain drugs patent portfolio to Grunenthal</title>
		<link>http://www.egenericdrugs.org/news/protect-sells-pain-drugs-patent-portfolio-to-grunenthal/</link>
		<comments>http://www.egenericdrugs.org/news/protect-sells-pain-drugs-patent-portfolio-to-grunenthal/#comments</comments>
		<pubDate>Fri, 11 Feb 2011 13:36:24 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2074</guid>
		<description><![CDATA[Protect Pharmaceutical, a New Jersey-based drug delivery and new product development company, has completed the sale of two patents and patents-applications related to pain drugs to German specialty pharmaceutical company Grunenthal. Lundbeck gets Cephalon products commercial rights in Canada, Latin Americ:  Copenhagen-headquartered Lundbeck, a developer and manufacturer of pharmaceutical products for the treatment of central [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/news/merck-wins-first-fosamax-state-court-case/' rel='bookmark' title='Merck wins first FOSAMAX state court case'>Merck wins first FOSAMAX state court case</a></li>
<li><a href='http://www.egenericdrugs.org/news/fda-grants-to-inhibitex-hcv-drug/' rel='bookmark' title='FDA grants to Inhibitex HCV drug'>FDA grants to Inhibitex HCV drug</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/protect-sells-pain-drugs-patent-portfolio-to-grunenthal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical Business Weekly Review</title>
		<link>http://www.egenericdrugs.org/news/pharmaceutical-business-weekly-review/</link>
		<comments>http://www.egenericdrugs.org/news/pharmaceutical-business-weekly-review/#comments</comments>
		<pubDate>Wed, 02 Feb 2011 12:49:29 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceutical Business]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2068</guid>
		<description><![CDATA[Paladin takes over Tempra from Bristol Myers Squibb Paladin Labs has acquired Tempra line of products from Bristol Myers Squibb in Canada including both syrup and drop formulations, under an agreement signed between both the companies. Pfizer Q4 revenue up 6% Pfizer has reported revenues of $17.56bn for the fourth quarter ended 31 December 2010, [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/news/merck-wins-first-fosamax-state-court-case/' rel='bookmark' title='Merck wins first FOSAMAX state court case'>Merck wins first FOSAMAX state court case</a></li>
<li><a href='http://www.egenericdrugs.org/new-drugs/fda-approves-amturnide-a-novartis-high-bp-drug/' rel='bookmark' title='FDA approves Amturnide a Novartis high BP drug'>FDA approves Amturnide a Novartis high BP drug</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/pharmaceutical-business-weekly-review/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diabetes on the rise</title>
		<link>http://www.egenericdrugs.org/news/diabetes-on-the-rise/</link>
		<comments>http://www.egenericdrugs.org/news/diabetes-on-the-rise/#comments</comments>
		<pubDate>Tue, 01 Feb 2011 18:52:45 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[prediabetes]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2063</guid>
		<description><![CDATA[Diabetes on the rise in USA. The CDC says more than 26 million Americans have Type 2 diabetes, and another 79 million have prediabetes. Those numbers are up from 2008, when 23.6 million had diabetes and 57 million had prediabetes. &#8220;These distressing numbers show how important it is to prevent type 2 diabetes and to [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/generic-drugs/generic-actos-pioglitazone-hydrochloride-diabetes-medicines/' rel='bookmark' title='Generic Actos &#8211; pioglitazone hydrochloride &#8211; Diabetes Medicines'>Generic Actos &#8211; pioglitazone hydrochloride &#8211; Diabetes Medicines</a></li>
<li><a href='http://www.egenericdrugs.org/new-drugs/the-innovative-medicines-initiative-news/' rel='bookmark' title='The Innovative Medicines Initiative news'>The Innovative Medicines Initiative news</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/diabetes-on-the-rise/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>High-dose clopidogrel no better than standard dose</title>
		<link>http://www.egenericdrugs.org/news/high-dose-clopidogrel-no-better-than-standard-dose/</link>
		<comments>http://www.egenericdrugs.org/news/high-dose-clopidogrel-no-better-than-standard-dose/#comments</comments>
		<pubDate>Tue, 01 Feb 2011 10:03:54 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[clopidogel]]></category>
		<category><![CDATA[plavix]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=2058</guid>
		<description><![CDATA[High-dose clopidogrel shows no better effect than standard dose in post-PCI patients at high risk of clots. Compared to a standard dose of clopidogrel, a higher dose of the anti-clotting agent did not reduce mortality, heart attack or the formation of in-stent blood clots in patients with high platelet reactivity who had undergone percutaneous coronary [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/generic-drugs/buy-generic-plavix-clopidogrel/' rel='bookmark' title='Buy Generic Plavix – clopidogrel'>Buy Generic Plavix – clopidogrel</a></li>
<li><a href='http://www.egenericdrugs.org/generic-drugs/generic-plavix-clopidogrel-cardiovascular-medicines/' rel='bookmark' title='Generic Plavix &#8211; clopidogrel &#8211; Cardiovascular Medicines'>Generic Plavix &#8211; clopidogrel &#8211; Cardiovascular Medicines</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/high-dose-clopidogrel-no-better-than-standard-dose/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Boehringer Ingelheim to acquire Amgen Fremont California facility</title>
		<link>http://www.egenericdrugs.org/news/boehringer-ingelheim-to-acquire-amgen-fremont-california-facility/</link>
		<comments>http://www.egenericdrugs.org/news/boehringer-ingelheim-to-acquire-amgen-fremont-california-facility/#comments</comments>
		<pubDate>Wed, 19 Jan 2011 21:43:08 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=510</guid>
		<description><![CDATA[Boehringer Ingelheim to acquire Amgen Fremont California facility. Boehringer Ingelheim is set to take over Amgen&#8217;s rights in and substantially all assets at its Fremont Callifornia development and manufacturing facility. Ironwood Pharma, Protagonist sign peptide drug discovery pact Ironwood Pharmaceuticals and Protagonist Therapeutics have signed a collaboration agreement for the discovery and development of peptide [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/news/fda-grants-to-inhibitex-hcv-drug/' rel='bookmark' title='FDA grants to Inhibitex HCV drug'>FDA grants to Inhibitex HCV drug</a></li>
<li><a href='http://www.egenericdrugs.org/news/forest-laboratories-to-acquire-clinical-data/' rel='bookmark' title='Forest Laboratories to acquire Clinical Data'>Forest Laboratories to acquire Clinical Data</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/boehringer-ingelheim-to-acquire-amgen-fremont-california-facility/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Boehringer, Eli Lilly to develop diabetes compounds</title>
		<link>http://www.egenericdrugs.org/news/boehringer-eli-lilly-to-develop-diabetes-compounds/</link>
		<comments>http://www.egenericdrugs.org/news/boehringer-eli-lilly-to-develop-diabetes-compounds/#comments</comments>
		<pubDate>Wed, 12 Jan 2011 16:30:11 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.egenericdrugs.org/?p=505</guid>
		<description><![CDATA[Boehringer, Eli Lilly to develop diabetes compounds. Boehringer Ingelheim and Eli Lilly and Company have entered into a global alliance to jointly develop and commercialise a portfolio of diabetes compounds currently in mid- and late-stage development. Amgen plans to widen use of Denosumab California-based Amgen is planning to build growth by widening the use of [...]
Related posts:<ol>
<li><a href='http://www.egenericdrugs.org/news/boehringer-ingelheim-to-acquire-amgen-fremont-california-facility/' rel='bookmark' title='Boehringer Ingelheim to acquire Amgen Fremont California facility'>Boehringer Ingelheim to acquire Amgen Fremont California facility</a></li>
<li><a href='http://www.egenericdrugs.org/news/sanofi-aventis-to-buy-genzyme/' rel='bookmark' title='Sanofi-Aventis to buy Genzyme'>Sanofi-Aventis to buy Genzyme</a></li>
</ol>]]></description>
		<wfw:commentRss>http://www.egenericdrugs.org/news/boehringer-eli-lilly-to-develop-diabetes-compounds/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

